interface MockResponse {
  response: string;
  sources: Array<{
    section: string;
    page?: number;
    content: string;
  }>;
  downloadableTemplates?: Array<{
    title: string;
    type: 'worksheet' | 'checklist' | 'report';
    filename: string;
  }>;
  quickActions?: Array<{
    title: string;
    icon: string;
    action: string;
    type: 'download' | 'generate' | 'setup';
  }>;
}

interface MockResponses {
  [key: string]: MockResponse;
}

// Exact demo responses for BI Trial 1404-0002 Diabetes Protocol
const DIABETES_PROTOCOL_RESPONSES: MockResponses = {
  
  // Query 1: "Give me the inclusion/exclusion criteria for male patients 50-65 yo"
  "inclusion_exclusion_male": {
    response: `# Eligibility Checklist: Male Patients 50-65 years - BI Trial 1404-0002

## INCLUSION CRITERIA ‚úÖ
- [x] **Male patients 18-75 years** (Protocol Section 3.3.2 #2)
- [x] **T2DM diagnosis ‚â•6 months prior** (Protocol Section 3.3.2 #3)  
- [x] **HbA1c 7.0%-10.0% at screening** (Protocol Section 3.3.2 #4)
- [x] **Stable metformin ‚â•1000mg/day for ‚â•3 months** (Protocol Section 3.3.2 #5)
- [x] **BMI 25-50 kg/m¬≤ at screening** (Protocol Section 3.3.2 #6)
- [x] **Signed informed consent** (Protocol Section 3.3.2 #1)

## EXCLUSION CRITERIA ‚ùå
- [ ] **Type 1 diabetes** (Protocol Section 3.3.3 #1)
- [ ] **HR >100 bpm or BP ‚â•160/95 mmHg** (Protocol Section 3.3.3 #7)
- [ ] **QT/QTc prolongation >450ms** (Protocol Section 3.3.3 #8)
- [ ] **Recent CV events within 6 months** (Protocol Section 3.3.3 #10)
- [ ] **eGFR <45 mL/min/1.73m¬≤** (Protocol Section 3.3.3 #19)
- [ ] **ALT/AST >2.5x ULN** (Protocol Section 3.3.3 #21)

### Age-Specific Considerations (50-65 years):
- Enhanced cardiovascular screening required
- Consider additional cardiac monitoring
- Review medication interactions carefully`,
    sources: [
      {
        section: "Section 3.3.2 Inclusion Criteria",
        page: 15,
        content: "Male and female patients aged 18-75 years with T2DM diagnosis ‚â•6 months prior to screening."
      },
      {
        section: "Section 3.3.3 Exclusion Criteria", 
        page: 16,
        content: "Patients with Type 1 diabetes, recent cardiovascular events within 6 months, or significant renal impairment."
      }
    ],
    quickActions: [
      {
        title: "Generate Screening Checklist",
        icon: "FileDown",
        action: "male_eligibility_screening_checklist.pdf",
        type: "generate"
      },
      {
        title: "Setup Age-Based Alerts",
        icon: "Bell",
        action: "setup_age_based_monitoring",
        type: "setup"
      },
      {
        title: "Create Assessment Form",
        icon: "Settings",
        action: "male_assessment_form.pdf",
        type: "generate"
      }
    ]
  },

  // Query 2: "What are the required medical test checklist"
  "medical_test_checklist": {
    response: `# Medical Tests Checklist - BI Trial 1404-0002

## SCREENING VISIT (Week -2) ü©∫
### Laboratory Tests Required:
- [ ] **HbA1c** (Central lab)
- [ ] **Complete Blood Count (CBC)**
- [ ] **Comprehensive Metabolic Panel (CMP)**
- [ ] **Liver Function Tests** (ALT, AST, Bilirubin)
- [ ] **Renal Function** (Creatinine, eGFR, BUN)
- [ ] **Lipid Profile** (Total, HDL, LDL, Triglycerides)
- [ ] **Urinalysis** + Microalbumin
- [ ] **TSH, Calcitonin**
- [ ] **Infectious Serology** (Hep B/C, HIV)

### Other Required Tests:
- [ ] **12-lead ECG** (triplicate)
- [ ] **Vital Signs** (BP, HR, temp, weight, height)
- [ ] **Physical Examination**
- [ ] **Pregnancy Test** (if applicable)
- [ ] **Urine Drug Screen**

## FOLLOW-UP VISITS (Weeks 2,4,8,12) üîÑ
- [ ] **Safety Labs** (CBC, CMP, LFTs)
- [ ] **HbA1c** (Week 12 only)
- [ ] **Vital Signs & Weight**
- [ ] **ECG**

### Critical Values - Immediate Action Required:
- Glucose <50 or >400 mg/dL
- ALT/AST >5x ULN
- Creatinine >2x baseline`,
    sources: [
      {
        section: "Section 5.2.3 Laboratory Tests Flow Chart",
        page: 28,
        content: "Complete blood count, comprehensive metabolic panel, and liver function tests required at screening and safety visits."
      },
      {
        section: "Section 5.2.6 Critical Lab Values",
        page: 31,
        content: "Immediate action required for glucose <50 or >400 mg/dL, ALT/AST >5x ULN, or creatinine >2x baseline."
      }
    ],
    quickActions: [
      {
        title: "Add this checklist to a patient",
        icon: "UserPlus",
        action: "add_checklist_to_patient",
        type: "setup"
      },
      {
        title: "Generate Test Checklist",
        icon: "FileDown",
        action: "medical_tests_checklist.pdf",
        type: "generate"
      },
      {
        title: "Create Lab Tracking Form",
        icon: "Settings",
        action: "lab_results_tracking_form.pdf",
        type: "generate"
      },
      {
        title: "Setup Critical Value Alerts",
        icon: "Bell",
        action: "setup_critical_value_alerts",
        type: "setup"
      }
    ]
  },

  // Query 3: "What is the visit checklist for each patient?"
  "visit_checklist": {
    response: `# Visit Worksheet: Follow-up Visit - BI Trial 1404-0002
**Visit**: Week 4 Follow-up | **Patient ID**: [________] | **Date**: [____/____/____]

## PRE-VISIT PREPARATION üìã
- [ ] Confirm patient compliance via diary review
- [ ] Review concomitant medications
- [ ] Patient fasted for biomarker samples (if applicable)

## REQUIRED PROCEDURES ‚úÖ

### 1. COMPLIANCE ASSESSMENT
- [ ] **Pill count** - Record number returned
- [ ] **Patient diary review** - SMBG data, injection sites
- [ ] **Concomitant medication changes** - Document any

### 2. EFFICACY EVALUATIONS  
- [ ] **Glucose monitoring data** download from device
- [ ] **Body weight measurement** (same scale)
- [ ] **Waist circumference** (if Week 4/12)

### 3. SAFETY MONITORING
- [ ] **Vital signs** (BP, HR, weight) - seated, 5min rest
- [ ] **Adverse event assessment** - new/ongoing AEs
- [ ] **Physical examination** (Week 4/12 only)
- [ ] **Laboratory tests** (CBC, CMP, LFTs if Week 4/12)
- [ ] **12-lead ECG**

### 4. DRUG ADMINISTRATION & DISPENSING
- [ ] **Study drug administration** (in clinic)
- [ ] **Check injection site reactions**
- [ ] **Dispense next visit supply** 

### 5. DATA COLLECTION
- [ ] **C-SSRS questionnaire**
- [ ] **eCRF completion**
- [ ] **Schedule next visit**

## CRITICAL SAFETY ALERTS ‚ö†Ô∏è
- FBG >240 mg/dL ‚Üí Contact site immediately
- QTcF >500ms ‚Üí Investigate, consider discontinuation
- Severe GI symptoms ‚Üí Assess for dose adjustment`,
    sources: [
      {
        section: "Section 4.3 Visit Procedures Flow Chart",
        page: 22,
        content: "Each visit requires compliance assessment, safety monitoring, efficacy evaluations, and data collection procedures."
      },
      {
        section: "Section 5.2.8 Critical Safety Parameters",
        page: 33,
        content: "FBG >240 mg/dL or QTcF >500ms require immediate investigation and potential discontinuation."
      }
    ],
    quickActions: [
      {
        title: "Generate Visit Worksheet",
        icon: "FileDown",
        action: "visit_worksheet_template.pdf",
        type: "generate"
      },
      {
        title: "Create Visit Checklist",
        icon: "Settings",
        action: "patient_visit_checklist.pdf",
        type: "generate"
      },
      {
        title: "Setup Visit Reminders",
        icon: "Bell",
        action: "setup_visit_reminders",
        type: "setup"
      }
    ]
  },

  // Query 4: "Give me an overview of the safety monitoring requirements"
  "safety_monitoring": {
    response: `# Safety Monitoring Requirements - BI Trial 1404-0002

## IMMEDIATE REPORTING (Within 24h) üö®
### Serious Adverse Events (SAEs):
- [ ] **Death, life-threatening events**
- [ ] **Hospitalization required**
- [ ] **Severe hypoglycemia** (<50 mg/dL with symptoms)
- [ ] **QTcF prolongation** >500ms or +60ms from baseline
- [ ] **Hepatic injury** (ALT/AST ‚â•3x ULN + Bilirubin ‚â•2x ULN)

### Adverse Events of Special Interest (AESIs):
- [ ] **Pancreatitis** 
- [ ] **Hepatic injury** (follow DILI checklist)

## ROUTINE MONITORING üìä
### Laboratory Safety (Weeks 4, 12):
**Critical Values Action Required**:
- Glucose <50 or >400 mg/dL
- Creatinine >2x baseline  
- ALT/AST >5x ULN
- Hemoglobin <8.0 g/dL

### Cardiovascular Monitoring:
- **ECG**: Triplicate at screening, then all visits
- **Vital Signs**: Every visit (BP <160/95, HR <100 bpm)
- **Discontinuation Criteria**: HR >120 bpm, QTcF >500ms

### Patient Self-Monitoring:
- **SMBG**: Weekly fasted measurements
- **Contact site if**: FBG >240 mg/dL or <70 mg/dL
- **Injection diary**: Date, time, site, reactions

## DATA SAFETY MONITORING BOARD (DSMB) üë•
- **Reviews**: Every 40 patients enrolled
- **Interim analysis**: At 50% enrollment  
- **Authority**: Can recommend study modification/termination

## EMERGENCY CONTACTS üìû
- **24/7 Emergency Line**: Available for severe hypoglycemia
- **Principal Investigator**: Immediate notification required
- **Medical Monitor**: Within 2 hours for SAEs`,
    sources: [
      {
        section: "Section 1.4.2 Safety Monitoring Overview",
        page: 8,
        content: "Comprehensive safety monitoring includes immediate SAE reporting, routine laboratory monitoring, and DSMB oversight."
      },
      {
        section: "Section 3.3.4.1 Discontinuation Criteria",
        page: 18,
        content: "QTcF >500ms or HR >120 bpm require immediate discontinuation consideration."
      },
      {
        section: "Section 5.2.6 Emergency Procedures",
        page: 31,
        content: "24/7 emergency contact required for severe hypoglycemia, immediate PI notification for all SAEs."
      }
    ],
    quickActions: [
      {
        title: "Generate Safety Checklist",
        icon: "FileDown",
        action: "safety_monitoring_checklist.pdf",
        type: "generate"
      },
      {
        title: "Create AE Report Form",
        icon: "Settings",
        action: "adverse_event_reporting_form.pdf",
        type: "generate"
      },
      {
        title: "Setup Safety Alerts",
        icon: "Bell",
        action: "setup_safety_alerts",
        type: "setup"
      }
    ]
  },

  // Query 5: "Generate a worksheet template for the schedule of activities in this protocol, including visits, procedures, and timelines."
  "generate_worksheet_template": {
    response: `# Visit Worksheet Template - Schedule of Activities

I've created a comprehensive **Visit Worksheet Template** specifically designed for BI Trial 1404-0002 follow-up visits. This template integrates all protocol-required procedures into an organized, easy-to-use format.

## üìã **What This Template Contains:**

### **1. Visit Information Header**
- Study ID and protocol reference
- Visit number and timeline (Week 8 ¬±3 days)
- Patient ID and staff assignment fields
- Date and time tracking

### **2. Patient Preparation Section**
- Pre-visit compliance review checklist
- Fasting requirements (none for this visit)
- Materials preparation confirmation
- Space for notes and observations

### **3. Required Procedures Table**
The template includes a structured table with the following procedures:

| **Procedure** | **Protocol Reference** | **Critical Notes** |
|---|---|---|
| **Efficacy Evaluation** | Section 4.3 | Blood glucose monitoring with result fields |
| **Urine Test (Ketones)** | Section 4.3 | Positive/Negative checkboxes + other field |
| **Symptom Questionnaire** | Section 4.3 | Fatigue, nausea assessment scoring |
| **Vital Signs** | Section 4.3 | BP and HR with specific result fields |

### **4. Safety Monitoring Alerts**
- **Critical thresholds** highlighted in red boxes
- **Immediate action items** for values outside normal ranges
- **Contact information** for emergency reporting

### **5. Data Capture & Compliance**
- EDC upload confirmation checkboxes
- Protocol deviation tracking
- Next steps and follow-up scheduling
- Staff signature and date fields

## üéØ **Key Features:**
- **Print-friendly format** optimized for clinical use
- **Large checkboxes** for easy marking
- **Generous spacing** for handwritten notes
- **Color-coded sections** for quick navigation
- **Professional GCP-compliant layout**

This template ensures consistent data collection across all follow-up visits while reducing administrative burden on clinical staff.`,
    sources: [
      {
        section: "Section 4.3 Visit Schedule and Procedures",
        page: 22,
        content: "Week 8 visit includes glucose monitoring, vital signs, symptom assessment, and adverse event monitoring."
      },
      {
        section: "Section 5.1 Data Collection Requirements",
        page: 26,
        content: "All visit data must be captured in EDC within 24 hours with source document verification."
      }
    ],
    downloadableTemplates: [
      {
        title: "Visit Worksheet Template",
        type: 'worksheet',
        filename: "visit_worksheet_week8_template.pdf"
      },
      {
        title: "Schedule of Activities",
        type: 'worksheet',
        filename: "schedule_of_activities_template.pdf"
      }
    ]
  },

  // Query 6: "Summarize inclusion/exclusion criteria for this protocol and generate a checklist for screening a patient with this profile: 45-year-old male, HbA1c 7.2%, history of hypertension"
  "patient_profile_checklist": {
    response: `# Patient Eligibility Assessment - 45-year-old Male Profile

I've analyzed the BI Trial 1404-0002 eligibility criteria and created a **patient-specific screening checklist** for your 45-year-old male patient with HbA1c 7.2% and hypertension history.

## üéØ **Initial Profile Assessment:**

### **‚úÖ Criteria Already Met:**
- **Age 45 years** ‚Üí Within 18-65 range ‚úÖ
- **HbA1c 7.2%** ‚Üí Within required 6.5-8.0% range ‚úÖ

### **‚ö†Ô∏è Risk Factor Identified:**
- **Hypertension history** ‚Üí Requires careful BP monitoring (exclusion if >160/100 mmHg)

## üìã **Generated Screening Checklist Contains:**

### **1. Inclusion Criteria Assessment**
- **Diabetes confirmation** with medical record verification
- **BMI measurement** (target 25-35 kg/m¬≤)
- **Metformin therapy verification** (‚â•3 months stable dose)
- **Pre-marked favorable criteria** (age, HbA1c already confirmed)

### **2. Exclusion Criteria Screening**
- **Blood pressure measurement protocol** (critical due to hypertension history)
- **Renal function assessment** (GFR calculation required)
- **Cardiovascular event timeline** (6-month lookback period)
- **Liver function verification**
- **Diabetes type confirmation**

### **3. Risk-Stratified Actions**
The checklist prioritizes tasks based on this patient's profile:

| **Priority Level** | **Required Action** | **Rationale** |
|---|---|---|
| üî¥ **HIGH** | Blood pressure measurement | Hypertension history - exclusionary if >160/100 |
| üü° **MEDIUM** | Comprehensive lab panel | Standard screening requirements |
| üü¢ **LOW** | Medical history review | Routine documentation |

### **4. Decision Framework**
- **Preliminary eligibility status** tracking
- **Conditional approval pathways** based on BP results
- **Next steps guidance** for borderline cases

### **5. Documentation & Compliance**
- **Staff signature sections** for accountability
- **Protocol deviation tracking** if modifications needed
- **Source document references** for audit trail

## üö® **Key Alert for This Patient:**
The checklist specifically highlights **blood pressure monitoring** as the primary screening focus due to the patient's hypertension history. BP must be <160/100 mmHg for study eligibility.

This personalized approach ensures efficient screening while maintaining protocol compliance.`,
    sources: [
      {
        section: "Section 3.1 Inclusion Criteria",
        page: 14,
        content: "Patients aged 18-65 years with Type 2 diabetes, HbA1c 6.5-8.0%, and stable metformin therapy for ‚â•3 months."
      },
      {
        section: "Section 3.2 Exclusion Criteria",
        page: 15,
        content: "Uncontrolled hypertension (>160/100 mmHg), recent cardiovascular events, and severe renal impairment are exclusionary."
      }
    ],
    downloadableTemplates: [
      {
        title: "Patient Eligibility Screening",
        type: 'checklist',
        filename: "patient_eligibility_screening_45yo.pdf"
      },
      {
        title: "Hypertension Assessment Form",
        type: 'worksheet',
        filename: "hypertension_assessment_form.pdf"
      }
    ]
  }
};

export function getMockResponse(query: string, documentId?: string): MockResponse {
  const normalizedQuery = query.toLowerCase();
  
  // Exact matching for demo queries
  if (normalizedQuery.includes('inclusion') && normalizedQuery.includes('exclusion') && normalizedQuery.includes('male') && normalizedQuery.includes('50-65')) {
    return DIABETES_PROTOCOL_RESPONSES.inclusion_exclusion_male;
  }
  
  if (normalizedQuery.includes('required medical test') && normalizedQuery.includes('checklist')) {
    return DIABETES_PROTOCOL_RESPONSES.medical_test_checklist;
  }
  
  if (normalizedQuery.includes('visit checklist') && normalizedQuery.includes('each patient')) {
    return DIABETES_PROTOCOL_RESPONSES.visit_checklist;
  }
  
  if (normalizedQuery.includes('overview') && normalizedQuery.includes('safety monitoring requirements')) {
    return DIABETES_PROTOCOL_RESPONSES.safety_monitoring;
  }
  
  if (normalizedQuery.includes('generate') && normalizedQuery.includes('worksheet template') && normalizedQuery.includes('schedule of activities')) {
    return DIABETES_PROTOCOL_RESPONSES.generate_worksheet_template;
  }
  
  if (normalizedQuery.includes('summarize') && normalizedQuery.includes('45-year-old male') && normalizedQuery.includes('hba1c 7.2')) {
    return DIABETES_PROTOCOL_RESPONSES.patient_profile_checklist;
  }
  
  // Default response for BI Trial 1404-0002
  return {
    response: `# BI Trial 1404-0002 - Document AI Assistant

I can help you with specific information about the BI Trial 1404-0002 diabetes protocol. Here are the main areas I can assist with:

## Available Queries:
### Patient Eligibility:
- **"Give me the inclusion/exclusion criteria for male patients 50-65 yo"**
- **"Summarize inclusion/exclusion criteria...45-year-old male, HbA1c 7.2%"**

### Clinical Procedures:
- **"What are the required medical test checklist"**
- **"What is the visit checklist for each patient?"**
- **"Give me an overview of the safety monitoring requirements"**

### Template Generation:
- **"Generate a worksheet template for the schedule of activities"**

### Key Protocol Information:
- **Study ID**: BI Trial 1404-0002
- **Phase**: Phase III
- **Population**: Type 2 Diabetes patients
- **Primary Endpoint**: HbA1c reduction from baseline

Please ask me one of the specific questions above, and I'll provide detailed information with downloadable templates and document references.`,
    sources: [
      {
        section: "Protocol Title Page",
        page: 1,
        content: "BI Trial 1404-0002: A randomized, double-blind, placebo-controlled study in patients with Type 2 diabetes mellitus."
      }
    ],
    downloadableTemplates: [
      {
        title: "Protocol Quick Reference",
        type: 'worksheet',
        filename: "bi_trial_quick_reference.pdf"
      }
    ]
  };
}

export function generateMockDocument(template: { title: string; type: string; filename: string }): Blob {
  // Generate realistic document content based on template type
  const currentDate = new Date().toLocaleDateString('en-US', { 
    year: 'numeric', 
    month: '2-digit', 
    day: '2-digit' 
  });
  
  let content = '';
  
  // Generate specific content based on template type and title
  if (template.title.toLowerCase().includes('screening') || template.title.toLowerCase().includes('eligibility')) {
    content = `<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <title>Patient Eligibility Screening</title>
    <style>
        body { font-family: Arial, sans-serif; margin: 40px; line-height: 1.6; color: #333; }
        .header { background: #f8f9fa; padding: 20px; margin-bottom: 30px; border: 2px solid #e9ecef; }
        .header h1 { margin: 0; color: #2c3e50; font-size: 20px; }
        .header .study-info { margin-top: 10px; font-size: 14px; color: #666; }
        .form-fields { background: #fff; border: 1px solid #ddd; padding: 20px; margin-bottom: 20px; }
        .form-fields h3 { margin-top: 0; color: #2c3e50; border-bottom: 2px solid #3498db; padding-bottom: 5px; }
        .field-row { display: flex; margin-bottom: 15px; align-items: center; }
        .field-label { font-weight: bold; width: 200px; margin-right: 10px; }
        .field-input { border-bottom: 1px solid #333; flex: 1; min-height: 20px; }
        .criteria-section { margin-bottom: 30px; }
        .criteria-section h3 { background: #3498db; color: white; padding: 10px; margin: 0; font-size: 16px; }
        .criteria-list { background: #f8f9fa; border: 1px solid #3498db; border-top: none; padding: 20px; }
        .criteria-item { display: flex; align-items: flex-start; margin-bottom: 12px; }
        .checkbox { width: 20px; height: 20px; border: 2px solid #333; margin-right: 15px; flex-shrink: 0; margin-top: 2px; }
        .criteria-text { flex: 1; }
        .signature-section { margin-top: 40px; border-top: 2px solid #333; padding-top: 20px; }
        .signature-row { display: flex; justify-content: space-between; margin-bottom: 30px; }
        .signature-box { width: 45%; }
        .signature-line { border-bottom: 1px solid #333; height: 30px; margin-bottom: 5px; }
        .date-box { width: 150px; border-bottom: 1px solid #333; height: 25px; }
    </style>
</head>
<body>
    <div class="header">
        <h1>PATIENT ELIGIBILITY SCREENING CHECKLIST</h1>
        <div class="study-info">
            <strong>Study Protocol:</strong> BI-1404-0002 | <strong>Generated:</strong> ${currentDate} | <strong>Version:</strong> 1.0
        </div>
    </div>

    <div class="form-fields">
        <h3>Patient Information</h3>
        <div class="field-row">
            <span class="field-label">Patient ID:</span>
            <div class="field-input"></div>
        </div>
        <div class="field-row">
            <span class="field-label">Date of Screening:</span>
            <div class="field-input"></div>
        </div>
        <div class="field-row">
            <span class="field-label">Staff Conducting Screening:</span>
            <div class="field-input"></div>
        </div>
    </div>

    <div class="criteria-section">
        <h3>INCLUSION CRITERIA</h3>
        <div class="criteria-list">
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">Male or female patients aged 18-75 years</div>
            </div>
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">Type 2 diabetes mellitus diagnosis ‚â•6 months prior to screening</div>
            </div>
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">HbA1c 7.0%-10.0% at screening visit</div>
            </div>
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">Stable metformin therapy ‚â•1000mg/day for ‚â•3 months</div>
            </div>
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">BMI 25-50 kg/m¬≤ at screening visit</div>
            </div>
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">Signed and dated informed consent</div>
            </div>
        </div>
    </div>

    <div class="criteria-section">
        <h3>EXCLUSION CRITERIA</h3>
        <div class="criteria-list">
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">Type 1 diabetes mellitus</div>
            </div>
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">Heart rate >100 bpm or BP ‚â•160/95 mmHg</div>
            </div>
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">QT/QTc prolongation >450ms (males) or >470ms (females)</div>
            </div>
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">Recent cardiovascular events within 6 months</div>
            </div>
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">eGFR <45 mL/min/1.73m¬≤</div>
            </div>
            <div class="criteria-item">
                <div class="checkbox"></div>
                <div class="criteria-text">ALT or AST >2.5x upper limit of normal</div>
            </div>
        </div>
    </div>

    <div class="form-fields">
        <h3>Assessment Results</h3>
        <div class="criteria-item">
            <div class="checkbox"></div>
            <div class="criteria-text"><strong>ELIGIBLE</strong> - All inclusion criteria met, no exclusion criteria</div>
        </div>
        <div class="criteria-item">
            <div class="checkbox"></div>
            <div class="criteria-text"><strong>INELIGIBLE</strong> - Reason: <span class="field-input" style="display: inline-block; width: 300px; margin-left: 10px;"></span></div>
        </div>
        <div class="criteria-item">
            <div class="checkbox"></div>
            <div class="criteria-text"><strong>PENDING</strong> - Additional tests required: <span class="field-input" style="display: inline-block; width: 250px; margin-left: 10px;"></span></div>
        </div>
    </div>

    <div class="signature-section">
        <div class="signature-row">
            <div class="signature-box">
                <div class="signature-line"></div>
                <div><strong>Staff Signature</strong></div>
            </div>
            <div class="signature-box">
                <div class="date-box"></div>
                <div><strong>Date</strong></div>
            </div>
        </div>
        <div class="signature-row">
            <div class="signature-box">
                <div class="signature-line"></div>
                <div><strong>Principal Investigator Review</strong></div>
            </div>
            <div class="signature-box">
                <div class="date-box"></div>
                <div><strong>Date</strong></div>
            </div>
        </div>
    </div>

    <div style="margin-top: 40px; text-align: center; font-size: 12px; color: #666; border-top: 1px solid #ddd; padding-top: 20px;">
        Generated by Themison Clinical AI Assistant | Document ID: ${template.filename.replace('.pdf', '')}_${Date.now()}
    </div>
</body>
</html>`;
  } else if (template.title.toLowerCase().includes('visit') || template.title.toLowerCase().includes('worksheet')) {
    content = `<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <title>Visit Worksheet</title>
    <style>
        body { font-family: Arial, sans-serif; margin: 40px; line-height: 1.5; color: #333; }
        .header { background: #f8f9fa; padding: 20px; margin-bottom: 30px; border: 2px solid #e9ecef; }
        .header h1 { margin: 0; color: #2c3e50; font-size: 20px; }
        .header .study-info { margin-top: 10px; font-size: 14px; color: #666; }
        .info-grid { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-bottom: 30px; }
        .info-box { border: 1px solid #ddd; padding: 15px; background: #fff; }
        .info-box h3 { margin-top: 0; color: #2c3e50; border-bottom: 2px solid #3498db; padding-bottom: 5px; }
        .field-row { display: flex; margin-bottom: 12px; align-items: center; }
        .field-label { font-weight: bold; width: 120px; margin-right: 10px; font-size: 14px; }
        .field-input { border-bottom: 1px solid #333; flex: 1; min-height: 20px; }
        .procedures-table { width: 100%; border-collapse: collapse; margin-bottom: 30px; font-size: 14px; }
        .procedures-table th { background: #3498db; color: white; padding: 12px; text-align: left; font-weight: bold; }
        .procedures-table td { padding: 12px; border: 1px solid #ddd; vertical-align: top; }
        .procedures-table tr:nth-child(even) { background: #f8f9fa; }
        .checkbox-large { width: 18px; height: 18px; border: 2px solid #333; margin-right: 10px; }
        .procedure-section { margin-bottom: 25px; }
        .procedure-section h3 { background: #34495e; color: white; padding: 12px; margin: 0; font-size: 16px; }
        .procedure-list { background: #f8f9fa; border: 1px solid #34495e; border-top: none; padding: 20px; }
        .procedure-item { display: flex; align-items: flex-start; margin-bottom: 10px; }
        .safety-alert { background: #ffe6e6; border: 2px solid #e74c3c; padding: 15px; margin: 20px 0; }
        .safety-alert h3 { color: #c0392b; margin-top: 0; }
        .signature-section { margin-top: 40px; border-top: 2px solid #333; padding-top: 20px; }
        .signature-row { display: flex; justify-content: space-between; margin-bottom: 25px; }
        .signature-box { width: 45%; }
        .signature-line { border-bottom: 1px solid #333; height: 30px; margin-bottom: 5px; }
    </style>
</head>
<body>
    <div class="header">
        <h1>VISIT WORKSHEET ‚Äì ${template.title}</h1>
        <div class="study-info">
            <strong>Study Protocol:</strong> BI-1404-0002 | <strong>Generated:</strong> ${currentDate} | <strong>Version:</strong> 1.0
        </div>
    </div>

    <div class="info-grid">
        <div class="info-box">
            <h3>Visit Information</h3>
            <div class="field-row">
                <span class="field-label">Visit:</span>
                <div class="field-input"></div>
                <span style="margin: 0 10px;">(Follow-up)</span>
            </div>
            <div class="field-row">
                <span class="field-label">Timeline:</span>
                <div class="field-input"></div>
                <span style="margin-left: 10px;">(¬±3 days)</span>
            </div>
        </div>
        <div class="info-box">
            <h3>Patient & Staff</h3>
            <div class="field-row">
                <span class="field-label">Patient ID:</span>
                <div class="field-input"></div>
            </div>
            <div class="field-row">
                <span class="field-label">Date of Visit:</span>
                <div class="field-input"></div>
            </div>
            <div class="field-row">
                <span class="field-label">Staff Name:</span>
                <div class="field-input"></div>
            </div>
        </div>
    </div>

    <div class="procedure-section">
        <h3>1. Patient Preparation</h3>
        <div class="procedure-list">
            <div><strong>Instructions:</strong> Confirm patient compliance via diary review. No fasting required.</div>
            <div style="margin-top: 15px;">
                <strong>Notes/Observations:</strong>
                <div class="field-input" style="margin-top: 5px; min-height: 40px;"></div>
            </div>
        </div>
    </div>

    <div class="procedure-section">
        <h3>2. Required Procedures</h3>
        <table class="procedures-table">
            <thead>
                <tr>
                    <th style="width: 30px;">#</th>
                    <th style="width: 200px;">Procedure</th>
                    <th style="width: 250px;">Action</th>
                    <th style="width: 150px;">Result</th>
                    <th>Comments/Deviations</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>1</td>
                    <td><strong>Efficacy Evaluation</strong><br>(Glucose Monitoring)</td>
                    <td>Measure blood glucose levels per protocol Section 4.3</td>
                    <td><div class="field-input" style="min-height: 25px;"></div> mg/dL</td>
                    <td><div class="field-input" style="min-height: 25px;"></div></td>
                </tr>
                <tr>
                    <td>2</td>
                    <td><strong>Urine Test</strong><br>(Ketones)</td>
                    <td>Collect and analyze urine sample</td>
                    <td>
                        <div style="display: flex; gap: 5px; align-items: center;">
                            <div class="checkbox-large"></div> Positive
                            <div class="checkbox-large"></div> Negative
                        </div>
                        Other: <div class="field-input" style="width: 80px; display: inline-block;"></div>
                    </td>
                    <td><div class="field-input" style="min-height: 25px;"></div></td>
                </tr>
                <tr>
                    <td>3</td>
                    <td><strong>Symptom Questionnaire</strong></td>
                    <td>Administer questionnaire on symptoms (fatigue, nausea, etc.)</td>
                    <td><div class="field-input" style="min-height: 25px;"></div></td>
                    <td><div class="field-input" style="min-height: 25px;"></div></td>
                </tr>
                <tr>
                    <td>4</td>
                    <td><strong>Vital Signs</strong></td>
                    <td>Measure blood pressure (BP) and heart rate (HR)</td>
                    <td>
                        <div style="margin-bottom: 5px;">BP: <div class="field-input" style="width: 80px; display: inline-block;"></div> mmHg</div>
                        <div>HR: <div class="field-input" style="width: 80px; display: inline-block;"></div> bpm</div>
                    </td>
                    <td><div class="field-input" style="min-height: 25px;"></div></td>
                </tr>
            </tbody>
        </table>
    </div>

    <div class="procedure-section">
        <h3>3. Additional Instructions</h3>
        <div class="procedure-list">
            <div class="procedure-item">
                <div class="checkbox-large"></div>
                <div>Monitor for adverse events (AEs). Report any to PI immediately.</div>
            </div>
            <div class="procedure-item">
                <div class="checkbox-large"></div>
                <div>Provide next dose if applicable.</div>
            </div>
            <div style="margin-top: 15px;">
                <strong>Notes:</strong>
                <div class="field-input" style="margin-top: 5px; min-height: 40px;"></div>
            </div>
        </div>
    </div>

    <div class="safety-alert">
        <h3>‚ö†Ô∏è Critical Safety Alerts</h3>
        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 15px;">
            <div>‚Ä¢ FBG >240 mg/dL ‚Üí Contact site immediately</div>
            <div>‚Ä¢ QTcF >500ms ‚Üí Investigate, consider discontinuation</div>
            <div>‚Ä¢ Severe GI symptoms ‚Üí Assess for dose adjustment</div>
            <div>‚Ä¢ Any serious adverse event ‚Üí Report within 24h</div>
        </div>
    </div>

    <div class="procedure-section">
        <h3>4. Data Capture Prompts</h3>
        <div class="procedure-list">
            <div class="procedure-item">
                <div class="checkbox-large"></div>
                <div><strong>Upload results to EDC:</strong></div>
                <div style="margin-left: 20px;">
                    <div class="checkbox-large"></div> Completed
                    <div class="checkbox-large"></div> Pending
                </div>
            </div>
            <div class="procedure-item">
                <div class="checkbox-large"></div>
                <div><strong>Record deviations:</strong></div>
                <div style="margin-left: 20px;">
                    <div class="checkbox-large"></div> None
                    <div class="checkbox-large"></div> Reported to: <div class="field-input" style="width: 150px; display: inline-block;"></div>
                </div>
            </div>
            <div style="margin-top: 15px;">
                <strong>Next Steps:</strong>
                <div class="field-input" style="margin-top: 5px; min-height: 40px;"></div>
            </div>
        </div>
    </div>

    <div class="signature-section">
        <div class="signature-row">
            <div class="signature-box">
                <div class="signature-line"></div>
                <div><strong>Staff Signature</strong></div>
            </div>
            <div class="signature-box">
                <div class="field-input" style="width: 120px; margin-bottom: 5px;"></div>
                <div><strong>Date Completed</strong></div>
            </div>
        </div>
    </div>

    <div style="margin-top: 30px; text-align: center; font-size: 12px; color: #666; border-top: 1px solid #ddd; padding-top: 15px;">
        <strong>Source:</strong> Protocol Section 4.3. Generated by Themison's RAG system, extracting visit-specific procedures and timelines from DIAB-2025-001 protocol.<br>
        Document ID: ${template.filename.replace('.pdf', '')}_${Date.now()}
    </div>
</body>
</html>`;
  } else if (template.title.toLowerCase().includes('test') || template.title.toLowerCase().includes('medical') || template.title.toLowerCase().includes('lab')) {
    content = `
BI TRIAL 1404-0002 - MEDICAL TESTS CHECKLIST
${template.title}

Study Protocol: BI-1404-0002
Date Generated: ${currentDate} ${currentTime}
Generated By: Themison Document AI Assistant

===============================================
MEDICAL TESTS CHECKLIST
===============================================

Patient ID: [____________________]
Visit Type: [____________________]
Date of Visit: [____/____/____]
Staff Name: [____________________]


SCREENING VISIT (Week -2) ü©∫

Laboratory Tests Required:
‚òê HbA1c (Central lab)
‚òê Complete Blood Count (CBC) 
‚òê Comprehensive Metabolic Panel (CMP)
‚òê Liver Function Tests (ALT, AST, Bilirubin)
‚òê Renal Function (Creatinine, eGFR, BUN)
‚òê Lipid Profile (Total, HDL, LDL, Triglycerides)
‚òê Urinalysis + Microalbumin
‚òê TSH, Calcitonin
‚òê Infectious Serology (Hep B/C, HIV)


Other Required Tests:
‚òê 12-lead ECG (triplicate)
‚òê Vital Signs (BP, HR, temp, weight, height)
‚òê Physical Examination
‚òê Pregnancy Test (if applicable)
‚òê Urine Drug Screen


FOLLOW-UP VISITS (Weeks 2,4,8,12) üîÑ

‚òê Safety Labs (CBC, CMP, LFTs)
‚òê HbA1c (Week 12 only)
‚òê Vital Signs & Weight
‚òê ECG


SAFETY ALERTS - Contact PI Immediately:

Critical Values Requiring Immediate Action:
‚Ä¢ Glucose <50 or >400 mg/dL
‚Ä¢ ALT/AST >5x ULN (Upper Limit of Normal)
‚Ä¢ Creatinine >2x baseline value

These values indicate potential safety issues that require:
- Immediate physician notification
- Patient assessment within 2 hours
- Possible study drug discontinuation
- Additional monitoring as directed by PI


COMPLETION CHECKLIST:
‚òê All required tests ordered
‚òê Results reviewed by study staff
‚òê Critical values addressed (if any)
‚òê Results entered into EDC system
‚òê Patient scheduled for next visit


Staff Signature: [____________________] Date: [____/____/____]
PI Review (for critical values): [____________________] Date: [____/____/____]
`;
  } else if (template.title.toLowerCase().includes('safety') || template.title.toLowerCase().includes('monitoring')) {
    content = `
BI TRIAL 1404-0002 - SAFETY MONITORING CHECKLIST
${template.title}

Study Protocol: BI-1404-0002
Date Generated: ${currentDate} ${currentTime}
Generated By: Themison Document AI Assistant

===============================================
SAFETY MONITORING CHECKLIST
===============================================

Patient ID: [____________________]
Monitoring Period: [____/____/____] to [____/____/____]
Staff Responsible: [____________________]

SERIOUS ADVERSE EVENTS (Report within 24h):
‚òê Death or life-threatening events
‚òê Hospitalization or prolonged hospitalization
‚òê Persistent/significant disability
‚òê Congenital anomaly/birth defect
‚òê Other medically important events

ADVERSE EVENTS OF SPECIAL INTEREST:
‚òê Severe hypoglycemia (<50 mg/dL with symptoms)
‚òê Pancreatitis (confirm with lipase/amylase)
‚òê Hepatic injury (ALT/AST ‚â•3x ULN + Bilirubin ‚â•2x ULN)
‚òê QTcF prolongation >500ms or +60ms from baseline

LABORATORY SAFETY MONITORING:
Critical Values - Take Action:
‚òê Glucose: [____] mg/dL (Action if <50 or >400)
‚òê Creatinine: [____] mg/dL (Action if >2x baseline)
‚òê ALT: [____] U/L (Action if >5x ULN)
‚òê AST: [____] U/L (Action if >5x ULN)
‚òê Hemoglobin: [____] g/dL (Action if <8.0)

CARDIOVASCULAR MONITORING:
‚òê ECG completed: QTcF [____] ms
‚òê Blood pressure: [____] mmHg (Target <160/95)
‚òê Heart rate: [____] bpm (Target <100)

EMERGENCY CONTACTS:
24/7 Emergency Line: 1-800-TRIAL-HELP
Principal Investigator: [____________________]
Medical Monitor: [____________________]

Actions Taken:
‚òê No action required
‚òê Follow-up scheduled: [____/____/____]
‚òê Study drug held: Reason [____________________]
‚òê Emergency contact made: Time [____] Contact [____________________]

Staff Signature: [____________________] Date: [____/____/____]
PI Review: [____________________] Date: [____/____/____]
`;
  } else {
    // Default template
    content = `
BI TRIAL 1404-0002 - ${template.title.toUpperCase()}

Study Protocol: BI-1404-0002
Date Generated: ${currentDate} ${currentTime}
Generated By: Themison Document AI Assistant

===============================================
${template.title.toUpperCase()}
===============================================

This document contains protocol-specific information for BI Trial 1404-0002.

Document Type: ${template.type}
Study Phase: Phase III
Population: Type 2 Diabetes Mellitus

[Template content would be customized based on the specific request]

Staff Signature: [____________________]
Date: [____/____/____]
`;
  }

  content += `

===============================================
DOCUMENT INFORMATION
===============================================
Document ID: ${template.filename.replace('.pdf', '')}_${Date.now()}
Version: 1.0
Status: Active
Generated: ${currentDate} ${currentTime}

===============================================
Generated with Themison Clinical AI Assistant
Powered by advanced RAG technology for clinical trials
Contact: support@themison.ai | Available 24/7
===============================================
`;
  
  // Return HTML for better formatting, or plain text for simple templates
  const isHTML = content.startsWith('<!DOCTYPE html>');
  return new Blob([content], { 
    type: isHTML ? 'text/html' : 'text/plain' 
  });
}